NCT07896460
A First-in-Human Study of BG-92505 Alone or in Combination With Other Anti-cancer Agents in Patients With Advanced Solid Tumors
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Number of Participants with Dose-Limiting Toxicities (DLTs)
Timeframe: Approximately 1 month
Number of Participants with Treatment-emergent Adverse Events, Treatment-related Adverse Events, and Serious Adverse Events
Timeframe: Approximately 24 months
Secondary (5)
Objective Response Rate (ORR)
Duration of response (DOR)
Disease Control Rate (DCR)
Progression-free Survival (PFS)
Plasma concentrations of BG-92505
Arms and interventions
Part A1: Monotherapy dose escalationExperimental
Ascending dose levels of BG-92505 will be evaluated as monotherapy in participants with selected advanced solid tumors.
Part A2: Monotherapy safety expansionExperimental
Selected dose levels of BG-92505 that have been determined to be safe in Monotherapy Dose Escalation, will be evaluated in participants with selected advanced solid tumors.
Part B: Combination Dose Escalation (BG-92505 + Anti-cancer agent)Experimental
Ascending dose levels of BG-92505 in combination with anti-cancer agent will be evaluated in participants with selected advanced solid tumors.
Drugs: BG-92505, Anti-Cancer Agent